Josh Blacher was named Chief Financial Officer of Imunon, Inc., succeeding Jeffrey Church, effective July 1, 2026. As of November 6, 2026, Imunon, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 30, 2026, naming 2 appointments and 1 departure (Form 8-K, June 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Imunon, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Jeffrey Church · Role: Chief Financial Officer · Effective: 2026-07-01 · 8-K, 2026-06-30
- · In / out: In · Person: Josh Blacher · Role: Chief Financial Officer · Effective: 2026-07-01 · 8-K, 2026-06-30
- · In / out: In · Person: Josh Blacher · 8-K, 2026-06-30
Imunon, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-30. It names 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Imunon, Inc. files it.
Also on the record for Imunon, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G/A, by Ayrton Capital LLC | — | 5%+ stakes | Source |
| August 12, 2025 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 4.99% of the class | 5%+ stakes | Source |
| May 28, 2025 | Form D, private offering | $3.25M sold | Form D page | Source |
Selling to them or working with them? See who runs Imunon, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Imunon, Inc. and the records around it.
Imunon, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing May 2025
- Who owns it
Companies that share a holder
- Ayrton Capital LLC also filed stake reports on 31 other companies: Bluejay Diagnostics, Inc. (Aug 2026), BTC Digital Ltd. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Imunon, Inc.
Get an email when Imunon, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Imunon, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Imunon, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Imunon, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-30 | Out | Chief Financial Officer | 2026-07-01 | 8-K, 2026-06-30 | |
| 2026-06-30 | In | Chief Financial Officer | 2026-07-01 | 8-K, 2026-06-30 | |
| 2026-06-30 | In | 8-K, 2026-06-30 |
Who leads Imunon, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Jeffrey Church, departure reported, effective 2026-07-01 (filed 2026-06-30). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Imunon, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Imunon, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Imunon, Inc.Every change, in the filing's words
Departing: Jeffrey Church, Chief Financial Officer, effective 2026-07-01
Retirement of interim Chief Financial Officer On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the "Company") of his intent to retire from the position of interim Chief Financial Officer (a position he has held since January of 2026), effective July 1, 2026 (the "Retirement Date").
Appointed: Josh Blacher, Chief Financial Officer, effective 2026-07-01
As a result of Mr. Church's retirement, effective July 1, 2026, the Company appointed Josh Blacher to serve as the Company's new interim Chief Financial Officer under a master services agreement (the "Agreement"), dated June 24, 2026, between the Company and Danforth Health, Inc., a financial advisory services firm ("Danforth").
Appointed: Josh Blacher
Mr. Blacher will serve as the Company's principal financial officer and principal accounting officer.
- To help ensure a smooth transition of his responsibilities to his successor, Mr. Church and the Company agreed that he will continue in a consulting role with the Company.
- The Company and Mr. Church amended the Consulting Agreement, effective July 1, 2026, pursuant to which, the Company agreed to pay Mr. Church a monthly retainer of $10,000 (that may be terminated upon 2 business days' notice).
- Mr. Church's departure is due to retirement and is without any disagreements with management.
- Mr. Blacher, age 54, currently serves as an employee of Danforth since September 2022, where he has worked as a chief financial officer in a consulting capacity for a number of life sciences companies as well as Managing Partner of Columbus Circle Capital LLC since August 2019.
- In his capacity as a consultant of Danforth, he has served as Chief Financial Officer of BullFrog AI Holdings, Inc. (Nasdaq: BFRG) since December 2024, among others.
- During his tenure at Columbus Circle Capital, Mr. Blacher has served as chief financial officer at several public and private companies.
Tools for this story
Each opens in a new tab, filled in for Imunon, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.